CAR-T

CAR-T Special Interest Group from Cell & Gene Therapy Insights

The future of CAR-T

Interested in sponsoring the SIG?

FIND OUT MORE

Aim

The Cell & Gene Therapy Insights CAR-T Special Interest Group (SIG) is an invitation-only initiative that brings senior experts together in small, closed-door working groups under the Chatham House Rule to build consensus, set priorities, and produce practical, open-access guidance for the field.

Who is invited

SIG members are invited from pharma, biotech, regulatory agencies, clinical practice, payer organizations, and academia to address one central question:

What has to change for CAR-T to reach the patients it was built for?

The 2027 focus

After a decade as the flagship modality in cell and gene therapy, CAR-T faces challenges that cut across every approach. Manufacturing is difficult to scale, costs limit access, the evidence base outside hematologic cancers remains thin, and regulatory and reimbursement frameworks are still catching up with new technologies. At the same time, advances in process and analytical technologies, gene delivery, and gene editing, along with expansion into autoimmune disease, are changing what the field can realistically aim for.

The 2026 SIG set out priorities for the next phase of CAR-T and identified the questions the field has yet to answer. In its second year, the SIG will focus on three of these:

  • How can manufacturing become faster, cheaper, and more consistent?
  • What evidence will regulators, payers, and clinicians need as CAR-T moves into solid tumors and autoimmune disease?
  • How can the benefits of CAR-T reach more of the patients who need them?

Steering Committee

Meet the members of the SIG Steering Committee, who advise on the SIG’s focus and discussion topics.

Bobby Goulding

Bobby Goulding

Director, Fate Therapeutics

Yu (Clay) Cao

Yu (Clay) Cao

Vice President and Global Head, Drug Discovery, GenEditBio

Alexey Bersenev

Dr. Bersenev received his medical education and certification as a general surgeon in Russia. He holds a PhD in transplantation/ pathology. He gained expertise in immunology, hematology, stem cell biology and published scientific papers during post-doctoral training in the US in Philadelphia at the Thomas Jefferson University and the Children’s Hospital of Philadelphia. He worked as a cell manufacturing specialist at the University of Pennsylvania and trained in clinical cell processing in a GMP cell manufacturing facility and was involved in the manufacture of CAR T-cell products for clinical trials and technology transfer to industry. He has expertise in clinical manufacturing of cellular products for clinical trials, including product and process development, cell processing and culture, operations of academic GMP facility and compliance with regulations. In addition to his position as Director of the Advanced Cell Therapy Lab at Yale-New Haven Hospital, he is an Assistant Professor of Clinical Laboratory Medicine at the Department of Laboratory Medicine at Yale University.

Alexey Bersenev

Assistant Professor, Clinical Laboratory Medicine, Yale University

Sven Kili

Dr. Sven Kili is a respected KOL in healthcare and biotechnology, boasting over 20 years of experience. He began as a surgeon in the NHS, where he gained valuable insights into patient care. Transitioning to Cell and Gene Therapies (CGT), Sven played key roles in leading the development, approval and commercialization of both a cell therapy and the first ex vivo gene therapy. With expertise across all stages of CGT development, he has built companies and teams in both large pharma/biotech and startups. Sven is a partner at Saisei Ventures, a boutique therapeutic venture investment firm focussed on creating and growing innovative companies, including with a focus on the Japanese CGT ecosystem. He also heads his consulting firm, Sven Kili Consulting Ltd., offering strategic guidance to organizations in the biotech and healthcare sectors. Most recently he served as the Chief Development Officer for CCRM (Centre for Commercialization of Regenerative Medicine) and OmniaBio. Sven actively contributes to industry boards and committees, including the BIA CGTAC, Innovation Hubs for Gene Therapy, ISCT, and ARM. Sven holds a visiting chair at UCL (University College London), where he heads the steering committee for a post-grad degree in Cell & Gene Therapy manufacturing and commercialisation. His dedication to advancing regenerative medicine and CGT is reflected in his multifaceted roles and ongoing efforts to shape the future of healthcare through innovation and strategic collaboration.

Sven Kili

Partner, Saisei Ventures & Principal, Sven Kili Consulting Ltd

Adrian Bot

Adrian Bot, M.D., Ph.D. is a biopharma executive with three decades of experience in research and development with a focus on immune, cell, gene therapy and nanomedicines, from start up to global, commercial stage companies. Most recently, he was the founding Chief Scientific Officer and Executive Vice President of R&D at Capstan Therapeutics, a company developing next generation RNA-based precision medicines. Previously, he held senior leadership roles at Kite Pharma and Kite — a Gilead Company, including Chief Scientific Officer, Global Head of Translational Medicine and Head of Discovery Research, respectively. At Kite, he contributed to the development of first-in-class CAR T cell therapy products for cancer. Previously, Dr. Bot served in various senior R&D leadership positions at MannKind Corp and Alliance Pharmaceutical Corp, La Jolla, California. He obtained his M.D. in Romania in 1993, his Ph.D. in Biomedical Sciences at Mount Sinai School of Medicine in New York in 1998 and subsequently, he was a Guest Scientist at the Scripps Research Institute in La Jolla, California. Dr. Bot is an inventor with multiple issued patents in the field of immunotherapy, and he authored or co-authored more than 200 peer reviewed manuscripts, abstracts, book chapters and monographs. He serves on the Board of Directors of Cartesian Therapeutics, Immuthera Bio and ImmunoScape, and serves as Advisor for AbbVie Inc, Stand Up 2 Cancer and other organizations. Dr. Bot participated in several exits to date: Kite Pharma initial public offering, Kite Pharma acquisition by Gilead Sciences and Capstan Therapeutics acquisition by AbbVie Inc.

Adrian Bot

Former CSO, Capstan Therapeutics

SIG members will be announced in early 2027.

Upcoming key dates and activities

The SIG’s work in 2027 centers on a series of closed-door working groups, taking place from June 14 to July 2. The Cell & Gene Therapy Insights editorial team then turns the consensus reached by members into a series of outputs published in the months that follow, setting out the field’s shared position and priorities.

2027 annual SIG:

June 14 – July 2, 2027 (virtual)

The initiative is formed by a series of small, closed-door working groups over three weeks, each focused on a single priority topic.

Working groups will cover areas such as:

  • Manufacturing by modality: autologous scale-up, allogeneic batch economics, and in vivo vector supply and release.
  • Process control and supply: potency through process change, automation and PAT, starting materials, and cost of goods.
  • Clinical evidence: earlier lines in hematologic malignancies, solid tumors, and autoimmune disease.
  • Access and commercial: reimbursement and outcomes-based agreements, and delivery capacity.

All SIG members meet under the Chatham House Rule. Each working group will produce consensus statements, which will form the basis of the outputs below.

White paper

A peer-reviewed white paper on a priority topic identified by the group.

Report

An in-depth, open-access consensus report with strategic recommendations for the field.

Further activities

These may include webinars, infographics, articles, in-person SIG member gatherings, and report-outs at major cell and gene therapy conferences.

To be kept informed about the progression and development of the SIG outputs, please register your interest.

REGISTER YOUR INTEREST

What members said about the 2026 SIG

“Fantastic opportunity for intellectual exchange with highly knowledgeable peers.”

– SIG member

“Appreciate the opportunity to connect with other developers and leaders in the field.”

– Steering Committee member and moderator

“Very professional meeting and productive workings.”

– Sponsor

“Great timing also, since data across a variety of technologies are becoming available.”

– Steering Committee member and moderator

To hear when each 2027 output is published

REGISTER YOUR INTEREST